Quarterly report pursuant to Section 13 or 15(d)

General (Details Narrative)

v3.21.2
General (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Jul. 27, 2020
Mar. 31, 2020
Dec. 31, 2019
Feb. 27, 2019
Accumulated losses $ (64,838) $ (47,281)        
Working capital 4,511          
Shareholders' deficit (19,458) (11,011)   $ (6,263) $ (6,249)  
Recognized revenue 5,031 5,207        
Credit Line [Member]            
Proceeds from issuance of financial instruments   2,617        
Straight loans [Member]            
Proceeds from issuance of financial instruments 1,677 1,574        
Private Placement Transactions [Member]            
Proceeds from issuance of financial instruments 255 2,368        
Convertible Bridge Loans Transactions [Member]            
Proceeds from issuance of financial instruments $ 4,012 $ 4,126        
Assignment of License Agreement [Member] | Breakthrough Diagnostics, Inc. [Member]            
Ownership percentage     80.01%     19.99%